Three designs that cannot become one recovery timetable

Laboratory endpoints, not diagnosed clot or bleeding events. The one-year visit and the 13-year interval have different clocks; platelet samples were stimulated outside the body.

Research comparisonObserved findingInterpretive limit
King 2017: one-year visitFibrinogen mean change +38.2 versus +42.6 mg/dL for visit abstainers versus smokers; no clear adjusted difference in fibrinogen or D-dimerUnadjusted changes are not treatment effects; recent seven-day abstinence is not a verified whole year
CARDIA 2013: visits 13 years apartAdjusted fibrinogen means increased in all four sex–race quit groups; comparative patterns were more favourable in some groupsSmaller increase is not a fall; 13 years between measurements is not everyone's abstinence duration
Onuma 2020: 12 analysed participants with usable samplesPhosphorylated HSP27 (Ser78) release after laboratory collagen stimulation: significance depended on selecting each person's higher four- or eight-week valueInitial time-point and four/eight-week average comparisons were not clear; no clinical clot-risk result

[1][2][3]

Protein concentration, breakdown fragment and platelet function are different

Fibrinogen is a liver-produced protein used to form fibrin. D-dimer is a fragment from breakdown of cross-linked fibrin, not a count of clots. Platelet count measures how many platelets are present; an aggregation or activation experiment measures a response under a specified protocol. A protein released by stimulated platelets is yet another endpoint. They are not interchangeable units of a single clotting score.

[2][4][5][6][7]

At one year, ‘not clearly different’ is not ‘unchanged in every person’

The Wisconsin study began with 1,652 smokers. Its longitudinal comparison used 888 people who made an aided quit attempt and attended the year-one assessment: 344 reported recent seven-day abstinence supported by exhaled carbon monoxide, and 544 were smoking at the visit. Treatment assignment did not randomly assign successful quitting. The visit was one year after a target quit date, not proof of continuous abstinence throughout that year.

Fibrinogen rose on average in both groups: +38.2 mg/dL in visit abstainers and +42.6 mg/dL in smokers. The reported standard deviations were 83.7 and 80.7 mg/dL, describing variation between participants, not confidence intervals or personal targets. Models accounting for baseline marker values, weight and insulin-resistance change did not show a clear abstinence difference in fibrinogen or D-dimer. Missing follow-up, other illness and residual confounding limit interpretation. This neither demonstrates normalization nor proves quitting can never affect those markers.

[1]

The longer study did not show a universal absolute fall

CARDIA measured fibrinogen at study year 7 and year 20, from 1992–1993 to 2005–2006, using nephelometry. Smoking categories came from reported status at those visits. Its adjusted Table 5 shows positive mean fibrinogen changes in all four sex–race groups classified as quitting; patterns relative to other smoking categories varied. A favourable comparison can mean less increase, not a lower final value or the same effect in every group. The 13-year observation interval cannot be relabelled as thirteen smoke-free years for every quitter. Selection, concurrent risk-factor changes and nonrandom quitting also matter.

[2]

Why a platelet headline needs the original analysis

The Japanese experiment reused samples from 15 cessation-clinic patients; samples from 12 participants were usable for analysis of released phosphorylated HSP27 (Ser78), not total HSP27. Samples were taken before and at four, eight and twelve weeks, then stimulated with collagen in the laboratory. The original time-point comparisons and the average of four/eight weeks were not statistically clear. Selecting each participant's higher four- or eight-week value produced a significant peak comparison; the authors acknowledged this analytical choice as a limitation.

That result is not evidence that quitting temporarily causes more clots, nor that twelve weeks establishes safety. It measured a selected protein-release response, not clinical events, platelet counts or medication effectiveness. It cannot justify continuing smoking, delaying quitting, choosing surgery timing or altering treatment.

[3]

Use the research question, not the table, to judge the conclusion

For a marker claim, keep the assay, population, comparator, observation interval and uncertainty attached. A change in a research assay cannot certify normal blood or rule in or rule out a personal clotting problem. Individual test or medicine questions belong with the responsible healthcare professional; this article supplies no thresholds, testing intervals or treatment choices. Separately, NHS Better Health directs readers in England to local Stop Smoking Services. Accessing support does not require showing a favourable coagulation result.

[4][5][6][7][8]

What to keep in mind

  • A marker change is not a measured clot or bleeding outcome.
  • Check whether improvement means a smaller rise and whether significance depends on a selected peak.

Sources

The central claims on this page were checked against the sources below.

  1. Arteriosclerosis, Thrombosis, and Vascular Biology: King et al. (2017): one-year fibrinogen and D-dimer comparison

    Sources checked: 2026-10-08

  2. Atherosclerosis: Okwuosa et al. (2013): fibrinogen change between CARDIA years 7 and 20

    Sources checked: 2026-10-08

  3. Internal Medicine: Onuma et al. (2020): stimulated platelet phosphorylated HSP27 (Ser78) release and peak-selection limits

    Sources checked: 2026-10-08

  4. MedlinePlus / US National Library of Medicine: D-dimer: fibrin-breakdown fragments and clinical context

    Sources checked: 2026-10-08

  5. MedlinePlus / US National Library of Medicine: Platelet count and platelet function are different measurements

    Sources checked: 2026-10-08

  6. MedlinePlus / US National Library of Medicine: Fibrinogen: the measured liver-produced protein

    Sources checked: 2026-10-08

  7. MSD Manual Consumer Version: Blood clotting: platelets, protein factors and fibrin

    Sources checked: 2026-10-08

  8. NHS Better Health: Finding local Stop Smoking Service support in England

    Sources checked: 2026-10-08

Population research education, not individual coagulation-test interpretation, clot or bleeding prediction, symptom assessment, medicine advice or surgical clearance.